Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microdosing psychedelics: Motivations, subjective effects and harm reduction
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
International Journal of Drug Policy (2019) Vol. 75, pp. 102600-102600
Closed Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 79
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 70
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Steven A. Barker
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1749-1763
Open Access | Times Cited: 38
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1329-1329
Open Access | Times Cited: 37
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial
Robin J. Murphy, Rachael L. Sumner, William J. Evans, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 6, pp. 511-521
Open Access | Times Cited: 30
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
Antonin Rouaud, Abigail E. Calder, Gregor Hasler
Journal of Psychopharmacology (2024) Vol. 38, Iss. 3, pp. 217-224
Open Access | Times Cited: 13
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine
Conor H. Murray, Joel Frohlich, Connor J. Haggarty, et al.
Neuropsychopharmacology (2024)
Closed Access | Times Cited: 13
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 60
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1316-1322
Open Access | Times Cited: 53
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
Josephine Marschall, George Fejer, Pascal Lempe, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 97-113
Open Access | Times Cited: 52
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Simon Vann Jones, Allison O’Kelly
Frontiers in Synaptic Neuroscience (2020) Vol. 12
Open Access | Times Cited: 51
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Nicolas G. Glynos, Christopher W. Fields, Julie Barron, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 4, pp. 379-388
Closed Access | Times Cited: 31
Psychotherapy with Psilocybin for Depression: Systematic Review
Jonathan Joseph Dawood Hristova, Virtudes Pérez‐Jover
Behavioral Sciences (2023) Vol. 13, Iss. 4, pp. 297-297
Open Access | Times Cited: 21
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan
Theresa M. Carbonaro, Matthew W. Johnson, Roland R. Griffiths
Psychopharmacology (2020) Vol. 237, Iss. 8, pp. 2293-2304
Open Access | Times Cited: 45
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
Friederike Holze, Matthias E. Liechti, Nadia R. P. W. Hutten, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 3, pp. 658-666
Open Access | Times Cited: 44
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Genís Oña, José Carlos Bouso
Neuroscience & Biobehavioral Reviews (2020) Vol. 119, pp. 194-203
Closed Access | Times Cited: 44
Motives for the use of serotonergic psychedelics: A systematic review
Lukas A. Basedow, Sören Kuitunen‐Paul
Drug and Alcohol Review (2022) Vol. 41, Iss. 6, pp. 1391-1403
Closed Access | Times Cited: 20
Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience
Madelene Palmer, Olivia Maynard
Harm Reduction Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 19
Psilocybin in Palliative Care: An Update
Emily Whinkin, Moira Opalka, Conor Watters, et al.
Current Geriatrics Reports (2023) Vol. 12, Iss. 2, pp. 50-59
Open Access | Times Cited: 12
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Kevin H. Yang, Nora Satybaldiyeva, Matthew R. Allen, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 6, pp. e241653-e241653
Open Access | Times Cited: 4
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data
Steven A. Barker
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111259-111259
Closed Access
Page 1 - Next Page

Scroll to top